Nanexa competitors & alternatives

Healthcare

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders. Its pipeline focuses on treating conditions such as suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder. The company utilizes a proprietary NMDA platform for its therapeutic developments.

Healthcare

Dicerna Pharmaceuticals was a biotechnology company that developed RNA interference (RNAi) therapeutics using its proprietary GalXC platform. It focused on medicines for patients with rare, chronic liver, cardiovascular, and metabolic diseases, and was acquired by Novo Nordisk in 2021.

Pharmaceuticals

Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.

Pharmaceuticals

Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.

OREXO AB OREXO0H19 · PharmaceuticalsUnited Kingdom

65% matchPublic

Pharmaceuticals

Orexo AB is a pharmaceutical company that specializes in developing innovative drug delivery technologies, notably its powder-based AmorphOX platform. The company advances proprietary and partnered pharmaceutical products, including treatments, vaccines, and nasal delivery formulations, serving patients and healthcare partners globally.

MEDINCELLMEDCL · PharmaceuticalsFrance

65% matchPublic

Pharmaceuticals

Medincell is a pharmaceutical and biotechnology company that develops long-acting injectable medications using its proprietary BEPO technology platform. The company provides therapeutic solutions, such as treatments for schizophrenia, in collaboration with pharmaceutical firms and health organizations to improve global health.

Surf Bio, Inc.BiotechnologyUnited States

64% matchPrivate

Biotechnology

Surf Bio, Inc. is a biotechnology company that collaborates with multinational pharmaceutical firms on drug delivery technologies and therapeutic pipelines.

Pharmaceuticals and Biotechnology

Anagenex is a biotechnology company that uses high-throughput experimentation, functional screening, and machine learning to discover small-molecule drug candidates. It focuses on challenging drug targets and works with biopharmaceutical companies as well as developing its own therapeutic programs.

Xanadu Bio, Inc.BiotechnologyUnited States

64% match

Biotechnology

Xanadu Bio, Inc. is a biotechnology company that develops next-generation polymer nanoparticle delivery platforms for mRNA and other nucleic acid-based therapies. Utilizing its proprietary poly(amine-co-ester) (PACE) polymer technology, the company creates tunable, organ-specific treatments for oncology and immunology, as well as intranasal vaccines for viral respiratory pathogens.

BIND TherapeuticsBiotechnologyUnited States

63% match

Biotechnology

BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.

Nosis BioBiotech

63% match

Biotech

Nosis Biosciences develops receptor-targeted RNA medicines utilizing its proprietary AI-powered platform, Connexa, which combines physics-aware deep learning, single cell biology, and high-throughput chemistry. The company's platform designs gene-silencing therapeutics intended to treat chronic conditions across various cell types and organ systems, including the heart, lungs, kidneys, and brain.

Flex PharmaPharmaceuticalsUnited States

63% match

Pharmaceuticals

Flex Pharma is a specialty pharmaceutical company that develops advanced drug delivery formulations to enhance the bioavailability, tolerability, and dosing flexibility of complex or poorly soluble drugs. The company utilizes its proprietary ElectroNanoSpray (ENS) technology platform to assist pharmaceutical innovators in optimizing drug performance for clinical trials and patient care.